Corcept Therapeutics Incorporated

CORT · Moat type: REGULIERUNG

MoatScore

2/10

Fair Value

25 USD

Margin of Safety

-262.6 %

Rating

MEIDEN

Corcept Therapeutics develops and markets drugs for modulating the cortisol signaling pathway, with revenue generated primarily through the sale of Korlym (mifepristone) to patients with Cushing's syndrome — a regulatory-protected niche product with de facto monopoly characteristics in its approved indication.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.